- Teva Pharm third-quarter profit tops estimates as branded drugs gain Reuters
- Teva jumps ahead of Q3 results Globes – Israel Business News
- Teva’s Innovative Portfolio Drives 11th Consecutive Quarter GlobeNewswire
- (TEVA) Teva Pharmaceutical Expects 2025 Adjusted EPS Range $2.55 – $2.65, vs. FactSet Est of $2.60 MarketScreener
- Teva ADR earnings beat by $0.10, revenue topped estimates Investing.com